27 Leukemia Clinical Trials in Buffalo, NY (2026)

Q: How do I join a clinical trial in Buffalo?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Buffalo research site will contact you.

Recruiting Leukemia Studies in Buffalo

NCT05099172Recruiting

First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)

Researchers are looking for a better way to treat people who have advanced non-small cell lung cancer (NSCLC), a group of lung cancers that have spread to nearby tissues or to other parts of the body....

Buffalo, NYPHASE1400 participantsBayer

View Study Details

NCT06780137Recruiting

A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)

Researchers are looking for new ways to treat people with extensive-stage small cell lung cancer (SCLC) that has relapsed or is refractory. Gocatamig is a new type of immunotherapy that uses a person'...

Buffalo, NYPHASE1327 participantsMerck Sharp & Dohme LLC

View Study Details

NCT04256317Recruiting

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

Study ASTX030-01 is a multi-phase study comprising of Phases 1-3 Monotherapy arms and a Phase 1 Combination Therapy arm Phase 1 Monotherapy consists of an open-label Dose Escalation Stage (Stage A) us...

Buffalo, NYPHASE2316 participantsTaiho Oncology, Inc.

View Study Details

NCT04686305Recruiting

Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC

DESTINY-Lung03 will investigate the safety and tolerability of trastuzumab deruxtecan in combination with Immunotherapy Agents with and without chemotherapy in patients with HER2 over-expressing non-s...

Buffalo, NYPHASE1304 participantsAstraZeneca

View Study Details

NCT07325136Recruiting

A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination With Nivolumab in Participants With Relapsed/Refractory Small Cell Lung Cancer

The purpose of this study is to assess the safety and tolerability of BMS-986525 alone and in combination with Nivolumab in participants with Relapsed/Refractory Small Cell Lung Cancer...

Buffalo, NYPHASE1240 participantsBristol-Myers Squibb

View Study Details

NCT06501196Recruiting

A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome

Study BH-30236-01 is a first-in-human (FIH), Phase 1/1b, open-label, dose escalation and expansion study in participants with relapsed/refractory acute myelogenous leukemia (R/R AML) or higher-risk my...

Buffalo, NYPHASE1170 participantsBlossomHill Therapeutics

View Study Details

NCT06414317Recruiting

An Education and Navigation Support Tool to Improve Participation in Care Coordination Among Patients With Locally Advanced, Metastatic and Unresectable Bladder Cancer and Their Caregivers

This clinical trial evaluates the impact of an education and navigation support tool (ENST) on patient and caregiver participation in care coordination for bladder cancer that has spread to nearby tis...

Buffalo, NYNA160 participantsRoswell Park Cancer Institute

View Study Details

NCT07504458Recruiting

Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia

This Phase 3 study in adult participants with newly diagnosed low-risk APL will evaluate the efficacy, safety, and PK of an oral capsule formulation of ATO, in combination with ATRA....

Buffalo, NYPHASE3150 participantsQuetzal Therapeutics

View Study Details

NCT05292521Recruiting

Quality of Life Intervention to Inform Patient Decision-Making in Early-Stage Lung Cancer

This clinical trial studies the effect of a quality of life intervention on decision-making in patients with early-stage lung cancer who are undergoing standard of care surgery or stereotactic body ra...

Buffalo, NYNA150 participantsRoswell Park Cancer Institute

View Study Details

NCT06323044Recruiting

MedSupport Intervention to Identify and Address Barriers to Pediatric Medication Adherence

This clinical trial identifies and addresses barriers to pediatric medication adherence among families of children with acute lymphoblastic leukemia. Pediatric nonadherence (noncompliance) to medicati...

Buffalo, NYNA150 participantsRoswell Park Cancer Institute

View Study Details

NCT06969430Recruiting

A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)

The primary purpose of Phase 1 is to assess the doses studied under Phase 1 (Dose Escalation) Arm A and identify the recommended dose (RD) for further development (Dose optimization). The primary obj...

Buffalo, NYPHASE1134 participantsDebiopharm International SA

View Study Details

NCT06824168Recruiting

Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission

This clinical two-arm trial is designed to evaluate two doses of quizartinib as maintenance therapy after induction/consolidation in participants with FMS-like tyrosine kinase 3 (FLT3)-internal tandem...

Buffalo, NYPHASE2130 participantsDaiichi Sankyo

View Study Details

NCT06116786Recruiting

A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer

The purpose of this study is to determine a safe and tolerable dose(s) of JNJ-86974680 for further research in combination with cetrelimab and radiation therapy....

Buffalo, NYPHASE1126 participantsJohnson & Johnson Enterprise Innovation Inc.

View Study Details

NCT05143840Recruiting

Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase

This study is a multicenter Phase 2, non-randomized, open-label single-group frontline study administering asciminib in patients with newly diagnosed Chronic Myeloid Leukemia-Chronic Phase (CML-CP). T...

Buffalo, NYPHASE2100 participantsAugusta University

View Study Details

NCT06074666Recruiting

Behavioral Parenting Skills as a Novel Target for Improving Pediatric Medication Adherence: Study 3

The current study will assess the acceptability and feasibility of the CareMeds intervention with a larger sample (N = 100) across multiple sites in Buffalo, NY, and Atlanta, GA....

Buffalo, NYNA100 participantsRoswell Park Cancer Institute

View Study Details

NCT06150664Recruiting

A Phase 1 of CTX-8371 in Patients With Advanced Malignancies

This is a Phase 1, open-label, first-in-human study of CTX-8371 administered as a monotherapy in patients with metastatic or locally advanced malignancies. The study will be conducted in 2 cohorts: Do...

Buffalo, NYPHASE185 participantsCompass Therapeutics

View Study Details

NCT07027514Recruiting

A Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer

A study of tolododekin alfa (also known as ANK-101) administered in combination with an anti-programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) antibody in participants with...

Buffalo, NYPHASE160 participantsAnkyra Therapeutics, Inc

View Study Details

NCT04919629Recruiting

APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion

This phase II trial studies the effect of APL-2 when given in combination with either pembrolizumab or pembrolizumab and bevacizumab compared with bevacizumab alone in treating patients with ovarian, ...

Buffalo, NYPHASE260 participantsRoswell Park Cancer Institute

View Study Details

NCT05143996Recruiting

CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

CLN-049-001 is a Phase 1, open-label, multicenter, first-in-human trial of CLN-049 in patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)...

Buffalo, NYPHASE160 participantsCullinan Therapeutics Inc.

View Study Details

NCT05442216Recruiting

Tagraxofusp and Azaxitadine With or Without Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents

A treatment cycle is 28 days for Cycle 1 and Cycle 2. Tagraxofusp will be administered at 12 mcg/kg IV over 15 minutes (-5 or +15 minutes) daily for 5 consecutive days (or 5 doses over a period not to...

Buffalo, NYPHASE253 participantsJoshua Zeidner

View Study Details

NCT04150497Recruiting

Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)

This is a first-in-human, open-label, dose escalation and expansion study of UCART22 administered intravenously to patients with relapsed or refractory B-cell acute Lymphoblastic Leukemia (B-ALL). The...

Buffalo, NYPHASE152 participantsCellectis S.A.

View Study Details

NCT06146257Recruiting

A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes

Study GLB-001-01 is a first-in-human (FIH), Phase 1, open-label, dose escalation and expansion clinical study of GLB-001 in participants with relapsed or refractory acute myeloid leukemia (R/R AML) or...

Buffalo, NYPHASE148 participantsGluBio Therapeutics Inc.

View Study Details

NCT03595917Recruiting

ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML

This research study is evaluating a drug called ABL001 taken in combination with dasatinib (Sprycel®) and prednisone (a steroid) as a possible treatment for B-cell Acute Lymphoblastic Leukemia that is...

Buffalo, NYPHASE140 participantsMarlise Luskin, MD

View Study Details

NCT07017829Recruiting

GT103 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic STK11 Mutant Non-Small Cell Lung Cancer

This phase II trial tests how well GT103 in combination with pembrolizumab works in treating patients with STK11 mutant non-small cell lung cancer that may have spread from where it first started to n...

Buffalo, NYPHASE228 participantsRoswell Park Cancer Institute

View Study Details

NCT04696575Recruiting

Lamivudine in Combination With Chemoimmunotherapy for the Treatment of Extensive Stage Small Cell Lung Cancer

This phase II trial studies the effect of lamivudine in combination with standard of care chemoimmunotherapy in treating patients with extensive stage small cell lung cancer. Even though small cell lu...

Buffalo, NYPHASE228 participantsRoswell Park Cancer Institute

View Study Details

NCT06871410Recruiting

Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

This phase I trial tests the safety, side effects, and best dose of genetically engineered cells (CD83 chimeric antigen receptor \[CAR\] T cells) in treating patients with acute myeloid leukemia (AML)...

Buffalo, NYPHASE126 participantsRoswell Park Cancer Institute

View Study Details

NCT06307548Recruiting

Fluorescence Image Guided Surgery Followed by Intraoperative Photodynamic Therapy for Improving Local Tumor Control in Patients With Locally Advanced or Recurrent Colorectal Cancer

\*As of June 2026- Phase I has been completed and we are now in Phase II. This phase I/II trial studies the side effects and how well fluorescence image guided surgery followed by intraoperative photo...

Buffalo, NYPHASE121 participantsRoswell Park Cancer Institute

View Study Details

About Leukemia Clinical Trials in Buffalo

Leukemia is a group of blood cancers that develop in the bone marrow and result in abnormal white blood cells. Types include acute myeloid (AML), acute lymphoblastic (ALL), chronic myeloid (CML), and chronic lymphocytic (CLL). Treatment varies by type and may include chemotherapy, targeted therapy, and stem cell transplant.

There are currently 27 leukemia clinical trials recruiting participants in Buffalo, NY. These studies are seeking a combined 3,518 participants. Research is being sponsored by Bayer, Merck Sharp & Dohme LLC, Taiho Oncology, Inc. and 16 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Leukemia Clinical Trials in Buffalo — FAQ

Are there leukemia clinical trials in Buffalo?

Yes, there are 27 leukemia clinical trials currently recruiting in Buffalo, NY. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Buffalo?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Buffalo research site will contact you about next steps.

Are clinical trials in Buffalo free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Buffalo studies also compensate for your time and travel.

What leukemia treatments are being tested?

The 27 active trials in Buffalo are testing new therapies including novel drugs, biologics, and treatment approaches for leukemia.

Data updated July 17, 2026 from ClinicalTrials.gov